Pure Global
NCT05340712

Evaluation of the Efficacy of a New Specific Infant Formula in Case of Functional Constipation

Evaluation of the Efficacy of a New Specific Infant Formula With a Prebiotic and Probiotics in Case of Functional Constipation
United Pharmaceuticals·ClinicalTrials.gov·dietary supplementRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Functional Constipation
Drug/Device/Intervention
new infant formula
Study type
Interventional
Intervention type
dietary supplement
Sponsor & location
Primary sponsor
United Pharmaceuticals
Location
Napoli,Napoli, Italy
Timeline & enrollment
Phase
N/A
Start date
Jul 20, 2022
End date
Sep 01, 2024
Enrollment
80 participants
Primary outcome

Hard stool consistency or painful defecation

Summary

This study aims to assess the clinical efficacy, safety and tolerance of a new formula
 containing a prebiotic and a mix of probiotics in the specific population of infants
 suffering from functional constipation through a superiority, double-blind, randomized,
 placebo-controlled trial.

ICD-10 classifications
ConstipationOther functional intestinal disordersFunctional intestinal disorder, unspecifiedOther specified functional intestinal disordersOther laxatives
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05340712
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05340712 through Pure Global AI's free database. This phase not specified trial is sponsored by United Pharmaceuticals and is currently Recruiting. The study focuses on Functional Constipation. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.